Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Germline predisposition to clonal hematopoiesis and its role in leukemia progression

Kelly Bolton • 1 Jun 2024
ASCO 2024
Leukemia

Kelly Bolton, MD, PhD, Washington University School of Medicine, St. Louis, MO, discusses germline predisposition to clonal hematopoiesis as a potential first step in leukemia progression. She highlights a study identifying novel genes that predispose to clonal hematopoiesis and stratifying leukemia risk based on these genetic markers. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kelly Bolton

CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists
Eric Padron et al. • 25 Mar 2024
9:25
The link between clonal hematopoiesis and COVID-19
Kelly Bolton • 10 Sep 2021

Related Videos

3:50
The real-world effectiveness of venetoclax-based therapy after BTKis in patients with CLL
Nilanjan Ghosh • 26 Jun 2024
3:13
Preliminary results from the FRIDA study: iadademstat and gilteritinib in FLT3-mutated R/R AML
Amir Fathi • 25 Jun 2024
1:42
First results of the APOLLO trial: ATRA-ATO versus SoC in high-risk acute promyelocytic leukemia
Uwe Platzbecker • 25 Jun 2024
4:42
The encouraging early results of NX-5948, a novel BTK degrader, in patients with R/R CLL and NHL
Kim Linton • 16 Jun 2024
The content of VJHemOnc is intended for healthcare professionals